.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,689,333

« Back to Dashboard

Claims for Patent: 4,689,333

Title: 2-(2-pyridylmethylthio (sulfinyl)) benzimidazoles
Abstract:The compound of the formula ##STR1## wherein R.sup.1 is hydrogen, methoxy or trifluoromethyl, R.sup.2 and R.sup.3 are independently hydrogen or methyl, R.sup.4 is a C.sub.2-5 fluorinated alkyl and n denotes 0 or 1, or a pharmacologically acceptable salt thereof is novel, and useful for prophylaxis and therapy of digestive ulcers (e.g. gastric ulcer, duodenal ulcer) and gastritis.
Inventor(s): Nohara; Akira (Kyoto, JP), Maki; Yoshitaka (Kyoto, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:06/937,193
Patent Claims: 1. A phramaceutical composition for preventing or treating digestive ulcers or gastritis, which contains an effective amount of a compound of the formula ##STR8## wherein R.sup.1 is hydrogen, methoxy or trifluoromethyl, R.sup.2 and R.sup.3 are independently hydrogen or methyl, R.sup.4 is a C.sub.2-5 fluorinated alkyl and n denotes 0 or 1, or a pharmacologically acceptable salt thereof, and pharmacologically acceptable carriers.

2. A phamaceutical composition according to claim 1, wherein R.sup.1 is hydrogen or trifluoromethyl.

3. A pharmaceutical composition according to claim 1, wherein R.sup.3 is hydrogen.

4. A pharmaceutical composition according to claim 1, wherein n is 1.

5. A phamaceutical composition according to claim 1, wherein R.sup.1 and R.sup.3 are hydrogen, R.sup.2 is methyl, R.sup.4 is 2,2,2-trifluoroethyl and n is 1.

6. A method for preventing or treating digestive ulcers or gastritis, which comprises administering a compound of the formula ##STR9## wherein R.sup.1 is hydrogen, methoxy or trifluoromethyl, R.sup.2 and R.sup.3 are independently hydrogen or methyl, R.sup.4 is a C.sub.2-5 fluorinated alkyl and n denotes 0 or 1, or a pharmacologically acceptable salt thereof, and pharmacologically acceptable carriers.

7. A method according to claim 6, wherein R.sup.1 is hydrogen or trifluoromethyl.

8. A method according to claim 6, wherein R.sup.3 is hydrogen.

9. A method according to claim 6, wherein n is 1.

10. A method according to claim 6, wherein R.sup.1 and R.sup.3 are hydrogen, R.sup.2 is methyl, R.sup.4 is 2,2,2-trifluoroethyl and n is 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc